THAR
Tharimmune·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Ample Liquidity
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About THAR
Tharimmune, Inc.
A biotechnology company developing drug candidates targeting the treatment of ferroptosis
34 Shrewsbury Avenue, Red Bank, NJ 07701
--
Tharimmune, Inc., was incorporated as a Delaware corporation on March 28, 2017. The company is a preclinical biotechnology company developing novel therapeutic candidates for iron death, an emerging anti-cancer mechanism that leads to IMCD for the treatment of drug-resistant cancers. The most advanced product candidate they have is HSB-1216, an IMCD inducer that targets a variety of solid tumors. The company uses its proprietary tumor targeting platform Quatrame to enhance the absorption of HSB-1216 in TME, prolong the duration of action and minimize off-target toxicity. In addition, their artificial intelligence precision medicine platform Trident is used to identify biomarkers in clinical programs to target specific patient groups.
Company Financials
EPS
THAR has released its 2025 Q2 earnings. EPS was reported at -0.64, versus the expected 0, missing expectations. The chart below visualizes how THAR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
